Form 4 for RGNX REGENXBIO Inc.
Accepted 2024-07-18 00:00:00 ET · period of report 2024-07-16 · accession 0001562180-24-005798 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2024-07-18 | 2024-07-16+ | RGNX | Mills Kenneth T. | Dir | M - OptEx | $3.76 | +2,410 | 410.2K | +0.6% | +$9,062 |
| DMT | 2024-07-18 | 2024-07-16+ | RGNX | Mills Kenneth T. | Dir | S - Sale+OE | $13.77 | -2,410 | 408.0K | -0.6% | -$33.2K |
| DMT | 2024-07-18 | 2024-07-16+ | RGNX | Mills Kenneth T. | Dir | M - OptEx | $0.00 | -2,410 | 81.2K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-16 | M | A | 200 | $3.76 | 408,235 | D | — | — | |
| 2 | Common | Common Stock | 2024-07-16 | S | D | 200 | $13.76 | 408,035 | D | — | — | |
| 3 | Common | Common Stock | 2024-07-17 | M | A | 2,210 | $3.76 | 410,245 | D | — | — | |
| 4 | Common | Common Stock | 2024-07-17 | S | D | 2,210 | $13.77 | 408,035 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $13.76 to $13.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 5 | Derivative | Stock Options (Right to Buy) | 2024-07-17 | M | D | 2,210 | $0.00 | 78,944 | D | $3.76 · — to 2025-05-19 | 2,210 Common Stock | (F3) The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. |
| 6 | Derivative | Stock Options (Right to Buy) | 2024-07-16 | M | D | 200 | $0.00 | 81,154 | D | $3.76 · — to 2025-05-19 | 200 Common Stock | (F3) The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. |